On December 1, 2020, drug manufacturer Novo Nordisk Inc. announced that, effective January 1, 2021, it “will no longer facilitate ‘bill-to/ship-to’ distribution of 340B product
Thanks to efforts by RWC-340B members and other covered entity advocates, 217 members of the House of Representatives signed a bipartisan letter to Health and
By letter dated October 30, 2020, Novartis is notifying covered entities that are federal grantees that they will continue to receive 340B discounts at contract
On October 9, 2020, RWC-340B and two of its member 340B grantee clinics, Cempa Community Cares and Matthew 25 AIDS Services, Inc., filed a lawsuit
Today, RWC-340B submitted to a letter to Secretary of the U.S. Department of Health and Human Services (HHS) Alex Azar requesting that HHS initiate enforcement
In a notice sent to covered entities and other 340B program participants, Eli Lilly and Co. (Lilly) announced that, effective September 1, 2020, it is
On August 26, Second Sight Solutions, the owner of the 340B ESP™ platform, hosted the second in a series of webinars on 340B ESP™. The
Here is a press statement from RWC-340B president Shannon Stephenson regarding the recent actions taken by drug manufacturers Lilly, Novartis, Merck, Sanofi, and Astra Zeneca.
This week, Kalderos announced that it is launching its new “340B Pay” platform which, if implemented, would fundamentally change how the 340B drug discount program
Earlier this week a third drug manufacturer, Novartis Pharmaceuticals, sent letters to 340B covered entities with contract pharmacy arrangements stating that beginning October 1, 2020,
